Memantinhydrochlorid Puren

Memantine Hydrochloride, the active ingredient in Memantinhydrochlorid Puren, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of Alzheimer’s disease in patients with moderate to severe cognitive impairment.

GNH USA supplies Memantinhydrochlorid Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Hydrochloride acts on the glutamatergic pathway to modulate neuronal excitotoxicity in neurodegenerative disease.

- Alzheimer’s disease: improves cognition, daily functioning and behavioral symptoms in patients with moderate to severe disease.

Memantine Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet. - Confusion: occasional disorientation, usually improves over time. - Fatigue: feeling unusually tired or weak. - Hypertension: modest increase in blood pressure.

Serious or Rare Side Effects: - Seizures: rare but may occur, requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, potentially life‑threatening. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic failure: signs of liver dysfunction such as jaundice. - Suicidal ideation: emergence of thoughts of self‑harm. - Psychosis: new or worsening hallucinations or delusions.

Before prescribing Memantinhydrochlorid Puren, clinicians should consider several safety factors.

- Renal impairment: adjust dose or monitor serum levels in patients with reduced kidney function. - Hepatic impairment: use with caution in patients with liver disease. - History of seizures: evaluate risk and monitor closely. - Elderly patients: start at low dose and titrate slowly. - Concomitant NMDA antagonists: avoid combined use due to additive effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine Hydrochloride can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can lead to excessive CNS depression. - Other NMDA antagonists: heightened risk of adverse neurological effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may reduce cognitive benefit of memantine. - CNS depressants (e.g., benzodiazepines): monitor for increased sedation. - Diuretics: may raise serum memantine concentrations; adjust dose if needed.